Skip to main content

Table 2 Change in symptoms, therapy and visual analogue scale (VAS) ratings between T0 and T1 (n = 35)

From: Diisocyanate-induced asthma in Switzerland: long-term course and patients’ self-assessment after a 12-year follow-up

  T0 T1 p-value
Upper airway symptoms 28 (80%) 9 (26%) <0.001
Asthma symptoms 34 (97%) 20 (57%) <0.001
Use of asthma medication* 31 (91%) 19 (56%) 0.002
Short acting beta2 agonists 19 (56%) 13 (38%) 0.18
Long acting beta2 agonists 10 (29%) 10 (29%) 1.0
Inhalable corticosteroids 26 (76%) 10 (29%) <0.001
Smokers 10 (29 %) 14 (40%) 0.05
VAS (cm) health status 1.2 (2.9) 8.0 (4.0) <0.001
VAS (cm) overall satisfaction 2.1 (6.1) 8.3 (3.4) <0.001
  1. Legend: Upper airway symptoms (conjunctivitis, rhinitis, hoarseness, pharyngeal irritant sensations); asthma symptoms (irritation, wheezing, chronic cough, chest tightness and dyspnoea); VAS = visual analogue scale. Data is presented as mean ± SD, median and interquartile range (IQR) or number (%).
  2. *n = 34.